

Amendments to the Claims:

1. (Currently Amended) A method of inducing the body to produce an antibody against the region of the CCR5 receptor in wild type individuals, that is affected by the delta 32 deletion comprising using a vaccine including a polypeptide having ~~the following sequence:~~the sequence disclosed in SEQ ID NO: 1.

~~Tyr Ser Gln Tyr Gln Phe Trp Lys Asn Phe Gln Thr Leu
Lys Ile Val Ile Leu Gly Leu Val Leu Pro Leu Leu Val
Met Val Ile Cys Tyr Ser Gly Ile Leu Lys Thr Leu Leu
Arg Cys Arg Asn Glu Lys Lys Arg.~~

2. (Currently Amended) The method according to claim 1 wherein the vaccine is a derivative of said polypeptide, having the sequence disclosed in SEQ ID NO: 2-3.

3. (Original) The method according to claim 1 wherein said vaccine produces an antibody bound to the CCR5 site.

4. (Currently Amended) A method of treating a patient infected with HIV comprising using a vaccine including a polypeptide having ~~the following sequence:~~ sequence disclosed in SEQ ID NO:1,

~~Tyr Ser Gln Tyr Gln Phe Trp Lys Asn Phe Gln Thr Leu~~
~~Lys Ile Val Ile Leu Gly Leu Val Leu Pro Leu Leu Val~~
~~Met Val Ile Cys Tyr Ser Gly Ile Leu Lys Thr Leu Leu~~
~~Arg Cys Arg Asn Glu Lys Lys Arg~~

wherein said vaccine produces an antibody against the region of the CCR5 receptor in wild type individuals, that is affected by the delta 32 deletion.

5. (Currently Amended) The method according to claim 2 wherein the vaccine is a derivative of said polypeptide as disclosed in SEQ ID NO:2 and 3.
6. (Currently Amended) A vaccine for producing an antibody against the region of the CCR5 receptor in wild type individuals, that is affected by the delta 32 deletion comprising a polypeptide having the ~~following sequence:~~ sequence disclosed in SEQ ID NO:1.

~~Tyr Ser Gln Tyr Gln Phe Trp Lys Asn Phe Gln Thr Leu~~
~~Lys Ile Val Ile Leu Gly Leu Val Leu Pro Leu Leu Val~~
~~Met Val Ile Cys Tyr Ser Gly Ile Leu Lys Thr Leu Leu~~
~~Arg Cys Arg Asn Glu Lys Lys Arg~~

7. (Original) A method of vaccination comprising providing a polypeptide that causes a body to generate antibodies in response to said polypeptide, said antibodies inactivating viral receptors.

8. (Currently Amended) The method according to claim 7 wherein said polypeptide has the following sequence: sequence disclosed in SEQ ID NO:1.

~~Tyr Ser Gln Tyr Gln Phe Trp Lys Asn Phe Gln Thr Leu Lys Ile Val Ile
Leu Gly Leu Val Leu Pro Leu Leu Val Met Val Ile Cys Tyr Ser Gly
Ile Leu Lys Thr Leu Leu Arg Cys Arg Asn Glu Lys Lys Arg~~

9. (Currently Amended) The method according to claim 8 wherein the vaccine is a derivative of said polypeptide as disclosed in SEQ ID NO: 2 and 3.

10. (Original) The method according to claim 9 wherein said vaccine produces an antibody bound to the CCR5 site.